Moleculin Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview

Moleculin Biotech

18/03/2024 20:22

* Moleculin Biotech Inc  MBRX.OQ   MBRX.O  is expected
to show no
change in quarterly revenue when it reports  results on March 20
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Moleculin Biotech Inc is
for a
loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Moleculin
Biotech
Inc is $3.00​, above​ its last closing price of $0.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.23       -0.24      -0.19     Beat    19.7
 Jun. 30 2023  -0.27       -0.27      -0.20     Beat    26.8
 Mar. 31 2023  -0.25       -0.25      -0.28     Missed  -12​
 Dec. 31 2022              -0.30      -0.23     Beat    24.2
 ​​Sep.        -0.27       -0.27      -0.30     Missed  -11.1
 30 2022                                                
 Jun. 30 2022  -0.25       -0.25      -0.24     Beat    4.6​
 Mar. 31 2022  -0.21       -0.21      -0.24     Missed  -13.5
 Dec. 31 2021              -0.21      -0.09     Beat    57.1
 This summary was machine generated March 18 at 20:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)